Edwards Q2 sales $1.4B (+49% YoY); raises FY2021 sales & adjusted EPS guidance

Edwards Lifesciences Corp

2021-Q2 EPS reported $1.31 revenue$2,592,600,000

Q2 2021 sales $1.4B, up 49% reported (44% underlying); diluted EPS $0.78, adjusted EPS $0.64.
TAVR sales $902M (+52% reported, +48% underlying); FY2021 TAVR growth guidance raised to ~20%.
Full-year 2021 sales guidance raised to $5.2–$5.4B (from $4.9–$5.3B); adjusted EPS guided to high end of $2.07–$2.27.
Q3 2021 guidance: sales $1.29–$1.37B, adjusted EPS $0.50–$0.56.
Free cash flow $457M; cash $2.6B; repurchased 1.3M shares for $112M in Q2.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.